Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
GENTAMICIN
Franklin Pharmaceuticals Ltd.
QJ01GB03
GENTAMICIN
100 Mg/Ml
Solution for Injection
POM
Equine Non Food
Gentamicin
Antibacterial
Authorised
1988-10-01
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Gentaject 10% Solution for Injection for Horses. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. A clear, sterile, almost colourless,aqueous solution for injection. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Horses (non food producing horses). 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of infections of the lower respiratory tract in horses caused by aerobic Gram-negative bacteria susceptible to gentamicin. 4.3 CONTRAINDICATIONS Do not use in known cases of renal dysfunction. Do not use in cases of known hypersensitivity to the active substance or to any of the excipients. Do not exceed the proposed dosing regimen. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Not applicable Each ml contains: ACTIVE SUBSTANCE Gentamicin (as gentamicin sulphate) 100 mg EXCIPIENTS Sodium Metabisulphite 1.0 mg Sodium Methyl parahydroxybenzoate (E219) 0.9 mg Sodium Propyl parahydroxybenzoate (E217) 0.1 mg HEALTH PRODUCTS REGULATORY AUTHORITY ________________________________________________________________________________________________________________________ _Date Printed 07/07/2015_ _CRN 7021440_ _page number: 1_ 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Horses: Gentamicin is well known to induce nephrotoxicity even at therapeutic doses. There are also isolated reports of ototoxicity with gentamicin. No margin of safety has been established under the approved dosing regimen. As such, gentamicin has a narrow margin of safety. The product should therefore only be used based on the benefit-risk assessment by the responsible veterinary surgeon for each individual horse, taking into account alternative available treatmen Read the complete document